Camlin Fine Sciences Q1 Results: Earnings call scheduled for Aug 11, 2026

1 min read     Updated on 04 Aug 2026, 07:39 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Camlin Fine Sciences Limited has announced a Q1 FY27 earnings conference call on August 11, 2026 at 5:00 PM IST to discuss unaudited financial results for the quarter ended June 30, 2026. The call will be led by Chairman & Managing Director Mr. Ashish Dandekar, Managing Director Mr. Nirmal Momaya, and CFO Mr. Santosh Parab. Dial-in access has been provided for participants across India, the USA, UK, Singapore, and Hong Kong. The intimation was filed by Company Secretary Rahul Sawale on August 4, 2026, in compliance with SEBI LODR Regulation 30.

powered bylight_fuzz_icon
47398129

*this image is generated using AI for illustrative purposes only.

Camlin Fine Sciences Limited has scheduled a Q1 FY27 earnings conference call on Tuesday, August 11, 2026 at 5:00 PM IST, to discuss the company's unaudited financial results for the quarter ended June 30, 2026. The intimation was filed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has clarified that discussions during the call will be based solely on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be discussed.

Call Details and Access Information

Investors and analysts are requested to pre-register for the call via the link provided by the company. The following dial-in access numbers have been made available for participation across multiple geographies:

Access Type: Details
Primary Number: +91 22 6280 1309 / +91 22 7115 8210
Toll Free – USA: 1 866 746 2133
Toll Free – UK: 0 808 101 1573
Toll Free – Singapore: 800 101 2045
Toll Free – Hong Kong: 800 964 448

Senior Management Participants

The earnings call will feature the following senior management representatives from Camlin Fine Sciences:

  • Mr. Ashish Dandekar – Chairman & Managing Director
  • Mr. Nirmal Momaya – Managing Director
  • Mr. Santosh Parab – Chief Financial Officer

RSVP and Investor Relations Contact

The call is being coordinated by Strategic Growth Advisors Pvt. Ltd. Interested participants may reach out to the investor relations team for further assistance:

Contact Person: Contact Number
Mr. Shrikant Sangani: +91 9619595686
Ms. Shaily Patwa: +91 9819494608

The company has noted that the scheduled date of the call is subject to change due to exigencies on the part of analysts, investors, or the company. The filing was signed by Rahul Sawale, Company Secretary & VP Legal, on August 4, 2026.

Historical Stock Returns for Camlin Fine Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.37%+2.24%-4.77%-22.87%-52.23%-27.36%

How might Camlin Fine Sciences' Q1 FY27 performance reflect the broader recovery trends in the global specialty chemicals sector?

What specific operational or strategic initiatives will management highlight to address potential margin pressures in the upcoming quarter?

Will the earnings call provide updated guidance on capital expenditure plans for capacity expansion in key product lines?

Camlin Fine Sciences promoter releases pledge on 4,000 shares

2 min read     Updated on 28 Jul 2026, 07:11 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Promoter Ashish Subhash Dandekar releases pledge on 4,000 shares of Camlin Fine Sciences on July 24, 2026. The move follows repayment of borrowings by the company. Encumbered holdings drop to 1,49,50,000 shares (7.78%).

powered bylight_fuzz_icon
46791655

*this image is generated using AI for illustrative purposes only.

Ashish Subhash Dandekar, a promoter of camlin fine sciences , has released a pledge on 4,000 equity shares of the company. The transaction was executed on July 24, 2026, and disclosed to stock exchanges on July 28, 2026. The release follows the repayment of borrowings by Camlin Fine Sciences Limited, reducing the promoter’s encumbered stake and signaling improved liquidity management within the group.

The disclosure was filed in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The notice was submitted to the National Stock Exchange of India Ltd., BSE Limited, and the Company Secretary of Camlin Fine Sciences Ltd. The action reduces the number of pledged shares held in favor of LRSD Securities Private Limited.

Transaction Details

Metric Value
Promoter Name Ashish Subhash Dandekar
Event Type Release of Pledge
Date of Event July 24, 2026
Shares Released 4,000
Pledgee Entity LRSD Securities Private Limited

Prior to this event, Ashish Subhash Dandekar held 1,97,78,510 equity shares, representing 10.30% of the total share capital. Of these, 1,49,54,000 shares (7.78% of total share capital) were already encumbered. The release of 4,000 shares brings the total encumbered holding down to 1,49,50,000 shares, which continues to represent 7.78% of the total share capital due to the negligible impact on the percentage stake.

Promoter Holding Structure

| Holding Category | No. of Shares | % of Total Share Capital | | ---: | :--- | | Total Promoter Holding | 1,97,78,510 | 10.30% | | Pre-Event Encumbered Shares | 1,49,54,000 | 7.78% | | Shares Released | 4,000 | 0.00% | | Post-Event Encumbered Shares | 1,49,50,000 | 7.78% |

The release of pledge is a routine corporate action that typically indicates the settlement of underlying debt obligations. In this case, the source document explicitly attributes the release to the repayment of borrowings by the target company. This reduction in encumbrance improves the promoter’s collateral buffer and reduces potential dilution risks associated with forced liquidation of pledged shares.

What the Numbers Show

While the absolute number of shares released (4,000) is small relative to the promoter’s total holding of nearly 1.98 crore shares, the action confirms active debt servicing by Camlin Fine Sciences. The fact that the company itself repaid the borrowings leading to the pledge release suggests that the debt obligation was likely corporate rather than personal to the promoter, or that the company facilitated the repayment to unencumber the promoter’s holdings. The remaining encumbered stake of 1.49 crore shares remains significant, indicating that a substantial portion of the promoter’s equity is still leveraged.

Historical Stock Returns for Camlin Fine Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+1.37%+2.24%-4.77%-22.87%-52.23%-27.36%

Will Camlin Fine Sciences continue to prioritize debt repayment to further reduce the promoter's remaining 7.78% encumbered stake?

How might this improvement in promoter liquidity influence investor sentiment and stock price volatility in the near term?

What is the source of funds used by Camlin Fine Sciences for this repayment, and does it impact the company's operational cash flow?

More News on Camlin Fine Sciences

1 Year Returns:-52.23%